Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Strong.ComebackStrong.Comeback is focusing on companies that experience declines in the last trading sessions but make significant recoveries to close higher.
11 Jul 2025$MREO Mereo BioPharma cratered 45% after its brittle bone disease treatment failed to hit early interim endpoints. The stock is sitting near its 52-week low ($1.58), and RSI remains neutral around 25, showing oversold but not extreme levels. With low beta (0.40) and sideways trend, there’s little technical momentum to suggest an immediate reversal. However, the pipeline remains active, and any partnership or data update could trigger a sharp bounce.
$WOLF Wolfspeed tumbled 34% after a meteoric 500% rally off its bankruptcy lows, with heavy profit-taking despite reducing debt. Trading volume exploded, and RSI at 43 indicates it's not deeply oversold yet. The stock remains in a downtrend below all key moving averages, signaling caution. Still, with high volatility and past explosive moves, day traders could catch a reflex bounce if momentum returns.
$CAPR Capricor Therapeutics slid 33% after the FDA rejected its DMD treatment, sending the stock to the lower end of its range. RSI at 38 shows modest oversold conditions, and volume surged to 7x its average. CAPR has rebounded sharply from past regulatory setbacks and remains in a sideways trend. If the company clarifies its regulatory path, the stock could bounce quickly.
Quick upside? Worth watching for a technical rebound, especially if a PR clarifies the FDA path.
$RARE Ultragenyx dropped 29% after a failed brittle bone disease study interim readout and an FDA complete response letter for gene therapy. Shares are at 52-week lows ($29.03) with RSI near 30, indicating borderline oversold. Analysts have cut targets but still hover around $65, double the current price, showing long-term potential. However, the trend remains sideways, and a clear near-term catalyst is absent.
upside? Possible technical bounce, but the lack of near-term catalysts makes this a cautious watch.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
